PEOPLE ON THE MOVE
Cerulean
Christopher Guiffre has been appointed President and CEO of Cerulean Pharma. Cerulean owns a pipeline of nanoparticle-drug conjugates (NDCs) targeted against cancer. Its lead candidate, CRLX101, is designed to concentrate in tumours and slowly release its anti-cancer molecule camptothecin. The therapy is currently in Phase II trials.
Guiffre has been Cerulean’s Chief Operating Officer since 2014, following a stretch as Senior Vice President and Chief Business Officer. He has also held senior positions at Alvos Therapeutics, Hydra Biosciences, and Cubist Pharmaceuticals.